Biotechnology company developing genetic medicines for neurological and central nervous system diseases
Biotechnology company developing genetic medicines for neurological and central nervous system diseases. It leverages human genetics and its TRACER AAV capsid discovery platform to develop therapies with improved delivery across the blood-brain barrier. Programs target diseases including Alzheimer’s, Friedreich’s ataxia, Parkinson’s disease, and ALS, with some programs advanced through partnerships.